Mutational Profile from Targeted NGS Predicts Survival in LDCT Screening–Detected Lung Cancers

Journal of Thoracic Oncology

Volumn 12, Issue 6, 2017, Pages 922-931

  Verri, Carla ^a   Borzi, Cristina ^a   Holscher, Todd ^b   Dugo, Matteo ^a   Devecchi, Andrea ^a   Drake, Katherine ^b   Sestini, Stefano ^a   Suatoni, Paola ^a   Romeo, Elisa ^b   Sozzi, Gabriella ^a   Pastorino, Ugo ^a   Boeri, Mattia ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b Gensignia Life Sciences Inc   (United States)

Author keywords

Low dose computed tomography; Lung cancer; MicroRNA based liquid biopsy; Mutational load; Next generation sequencing

Indexed keywords

K RAS PROTEIN; PROTEIN P53; TUMOR MARKER;

ADULT; ARTICLE; BLOOD SAMPLING; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; FEMALE; GENE IDENTIFICATION; GENE MUTATION; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; INTERMEDIATE RISK PATIENT; LIQUID BIOPSY; LOW ENERGY RADIATION; LOW RISK PATIENT; LUNG ADENOCARCINOMA; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; NEXT GENERATION SEQUENCING; PRIORITY JOURNAL; RNA ANALYSIS; SMALL CELL LUNG CANCER; SMOKING HABIT; SQUAMOUS CELL LUNG CARCINOMA; SURVIVAL PREDICTION; X-RAY COMPUTED TOMOGRAPHY; ADENOCARCINOMA; EARLY CANCER DIAGNOSIS; FOLLOW UP; GENETICS; HIGH THROUGHPUT SEQUENCING; LUNG TUMOR; MIDDLE AGED; MORTALITY; MUTATION; PATHOLOGY; PROCEDURES; PROGNOSIS; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE;

ADENOCARCINOMA; ADULT; BIOMARKERS, TUMOR; CARCINOMA, SQUAMOUS CELL; EARLY DETECTION OF CANCER; FEMALE; FOLLOW-UP STUDIES; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; SMALL CELL LUNG CARCINOMA; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 85015997533     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1016/j.jtho.2017.03.001     Document Type: Article

References (41)

1. Islami, F., Torre, L.A., Jemal, A., Global trends of lung cancer mortality and smoking prevalence. Transl Lung Cancer Res 4 (2015), 327–338.
2. Siegel, R., Naishadham, D., Jemal, A., Cancer statistics, 2013. CA Cancer J Clin 63 (2013), 11–30.
3. Midthun, D.E., Jett, J.R., Screening for lung cancer: the US studies. J Surg Oncol 108 (2013), 275–279.
4. Field, J.K., van Klaveren, R., Pedersen, J.H., et al. European randomized lung cancer screening trials: post NLST. J Surg Oncol 108 (2013), 280–286.
5. National Lung Screening Trial Research Team, Aberle, D.R., Adams, A.M., et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 365 (2011), 395–409.
6. Pastorino, U., Rossi, M., Rosato, V., et al. Annual or biennial CT screening versus observation in heavy smokers: 5-year results of the MILD trial. Eur J Cancer Prev 21 (2012), 308–315.
7. Saghir, Z., Dirksen, A., Ashraf, H., et al. CT screening for lung cancer brings forward early disease. The randomised Danish Lung Cancer Screening Trial: status after five annual screening rounds with low-dose CT. Thorax 67 (2012), 296–301.
8. Infante, M., Cavuto, S., Lutman, F.R., et al. Long-term follow-up results of the DANTE trial, a randomized study of lung cancer screening with spiral computed tomography. Am J Respir Crit Care Med 191 (2015), 1166–1175.
9. McMahon, P.M., Kong, C.Y., Bouzan, C., et al. Cost-effectiveness of computed tomography screening for lung cancer in the United States. J Thorac Oncol 6 (2011), 1841–1848.
10. Patz, E.F. Jr., Pinsky, P., Gatsonis, C., et al. Overdiagnosis in low-dose computed tomography screening for lung cancer. JAMA Intern Med 174 (2014), 269–274.
11. Bach, P.B., Mirkin, J.N., Oliver, T.K., et al. Benefits and harms of CT screening for lung cancer: a systematic review. JAMA 307 (2012), 2418–2429.
12. Tanner, N.T., Kanodra, N.M., Gebregziabher, M., et al. The association between smoking abstinence and mortality in the National Lung Screening Trial. Am J Respir Crit Care Med 193 (2016), 534–541.
13. Pastorino, U., Boffi, R., Marchiano, A., et al. Stopping smoking reduces mortality in low-dose computed tomography screening participants. J Thorac Oncol 11 (2016), 693–699.
14. Montani, F., Marzi, M.J., Dezi, F., et al. miR-test: a blood test for lung cancer early detection. J Natl Cancer Inst, 107, 2015, djv063.
15. Xing, L., Su, J., Guarnera, M.A., et al. Sputum microRNA biomarkers for identifying lung cancer in indeterminate solitary pulmonary nodules. Clin Cancer Res 21 (2015), 484–489.
16. Sestini, S., Boeri, M., Marchiano, A., et al. Circulating microRNA signature as liquid-biopsy to monitor lung cancer in low-dose computed tomography screening. Oncotarget 20 (2015), 32868–32877.
17. Boeri, M., Verri, C., Conte, D., et al. MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc Natl Acad Sci U S A 108 (2011), 3713–3718.
18. Sozzi, G., Boeri, M., Rossi, M., et al. Clinical utility of a plasma-based miRNA signature classifier within computed tomography lung cancer screening: a correlative MILD trial study. J Clin Oncol 32 (2014), 768–773.
19. Pastorino, U., Bellomi, M., Landoni, C., et al. Early lung-cancer detection with spiral CT and positron emission tomography in heavy smokers: 2-year results. Lancet 362 (2003), 593–597.
20. Boeri, M., Sestini, S., Fortunato, O., et al. Recent advances of microRNA-based molecular diagnostics to reduce false-positive lung cancer imaging. Expert Rev Mol Diagn 15 (2015), 801–813.
21. Fortunato, O., Boeri, M., Verri, C., et al. Assessment of circulating microRNAs in plasma of lung cancer patients. Molecules 19 (2014), 3038–3054.
22. de Leng, W.W., Gadellaa-van Hooijdonk, C.G., Barendregt-Smouter, F.A., et al. Targeted next generation sequencing as a reliable diagnostic assay for the detection of somatic mutations in tumours using minimal DNA amounts from formalin fixed paraffin embedded material. PLoS One, 11, 2016, e0149405.
23. Dinse, G.E., Lagakos, S.W., Nonparametric estimation of lifetime and disease onset distributions from incomplete observations. Biometrics 38 (1982), 921–932.
24. Belloni, E., Veronesi, G., Rotta, L., et al. Whole exome sequencing identifies driver mutations in asymptomatic computed tomography-detected lung cancers with normal karyotype. Cancer Genet 208 (2015), 152–155.
25. Clinical Lung Cancer Genome Project, Network Genomic Medicine. A genomics-based classification of human lung tumors. Sci Transl Med, 5, 2013, 209ra153.
26. Herbst, R.S., Heymach, J.V., Lippman, S.M., Lung cancer. N Engl J Med 359 (2008), 1367–1380.
27. Imielinski, M., Berger, A.H., Hammerman, P.S., et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 150 (2012), 1107–1120.
28. Pan, W., Yang, Y., Zhu, H., Zhang, Y., Zhou, R., Sun, X., KRAS mutation is a weak, but valid predictor for poor prognosis and treatment outcomes in NSCLC: a meta-analysis of 41 studies. Oncotarget 7 (2016), 8373–8388.
29. Pao, W., Miller, V., Zakowski, M., et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101 (2004), 13306–13311.
30. Yanagawa, N., Shiono, S., Abiko, M., Katahira, M., Osakabe, M., Ogata, S.Y., The clinical impact of solid and micropapillary patterns in resected lung adenocarcinoma. J Thorac Oncol 11 (2016), 1976–1983.
31. Warth, A., Cortis, J., Soltermann, A., et al. Tumour cell proliferation (Ki-67) in non-small cell lung cancer: a critical reappraisal of its prognostic role. Br J Cancer 111 (2014), 1222–1229.
32. Boeri, M., Pastorino, U., Sozzi, G., Role of microRNAs in lung cancer: microRNA signatures in cancer prognosis. Cancer J 18 (2012), 268–274.
33. McAllister, S.S., Weinberg, R.A., The tumour-induced systemic environment as a critical regulator of cancer progression and metastasis. Nat Cell Biol 16 (2014), 717–727.
34. Huang, J., Wu, J., Li, Y., et al. Deregulation of serum microRNA expression is associated with cigarette smoking and lung cancer. Biomed Res Int, 2014, 2014, 364316.
35. Fabbri, M., Paone, A., Calore, F., et al. MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response. Proc Natl Acad Sci U S A 109 (2012), E2110–E2116.
36. Fernandez-Messina, L., Gutierrez-Vazquez, C., Rivas-Garcia, E., Sanchez-Madrid, F., de la, F.H., Immunomodulatory role of microRNAs transferred by extracellular vesicles. Biol Cell 107 (2015), 61–77.
37. He, W.A., Calore, F., Londhe, P., Canella, A., Guttridge, D.C., Croce, C.M., Microvesicles containing miRNAs promote muscle cell death in cancer cachexia via TLR7. Proc Natl Acad Sci U S A 111 (2014), 4525–4529.
38. Chen, V.W., Ruiz, B.A., Hsieh, M.C., Wu, X.C., Ries, L.A., Lewis, D.R., Analysis of stage and clinical/prognostic factors for lung cancer from SEER registries: AJCC staging and collaborative stage data collection system. Cancer 120:suppl 23 (2014), 3781–3792.
39. International Early Lung Cancer Action Program Investigators, Henschke, C.I., Yankelevitz, D.F., et al. Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med 355 (2006), 1763–1771.
40. Howington, J.A., Blum, M.G., Chang, A.C., Balekian, A.A., Murthy, S.C., Treatment of stage I and II non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 143 (2013), e278S–e313S.
41. The Cancer Genome Atlas. http://cancergenome.nih.gov. Accessed November 20, 2015.